selamectin profile

selamectin: a broad-spectrum endectocide; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	9578507
CHEMBL ID	1908325
CHEBI ID	177562
SCHEMBL ID	120105
MeSH ID	M0371163
PubMed CID	122198140
MeSH ID	M0371163

Synonym
CHEBI:177562
(1r,4s,5's,6r,6's,8r,10e,12s,13s,14e,16e,20r,21z,24s)-6'-cyclohexyl-24-hydroxy-21-hydroxyimino-12-[(2r,4s,5s,6s)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-5',11,13,22-tetramethylspiro[3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetrae
D05813
selamectin (usan/inn)
NCGC00095066-01
25-cyclohexyl-25-de(1-methylpropyl)-5-deoxy-22 23-dihydro-5-(hydroxyimino)-avermectin b1 monosaccharide
(2ae,4e,5's,6s,6's,7s,8e,11r,13r,15s,17ar,20ar,20bs)-6'-cyclohexyl-7-((2,6-dideoxy-3-o-methyl-alpha-l-arabino-hexopyranosyl)oxy)-3',4',5',6,6',7,10,11,14,15,20a,20b-dodecahydro-20b-hydroxy-5',6,8,19-tetramethylspiro(11,15-methano-2h,13h,17h-furo(4,3,2-pq)
25-cyclohexyl-4'-o-de(2,6-dideoxy-3-o-methyl-alpha-l-arabino-hexopyranosyl)-5-demethoxy-25-de(1-methylpropyl)-22,23-dihydro-5-(hydroxyimino)-avermectin a1a
uk-124,114
revolution (antibiotic)
a2669owx9n ,
unii-a2669owx9n
selamectin [usan:inn:ban]
nsc 758615
avermectin a1a, 25-cyclohexyl-4'-o-de(2,6-dideoxy-3-o-methyl-alpha-l-arabino-hexopyranosyl)-5-demethoxy-25-de(1-methylpropyl)-22,23-dihydro-5-(hydroxyimino)-, (5z)-
uk 124114
revolution
tox21_111408
cas-165108-07-6
dtxcid4025903
dtxsid6045903 ,
uk-124114
CHEMBL1908325
selamectin [usp-rs]
selamectin component of stronghold
selamectin [green book]
stronghold component selamectin
selamectin [mart.]
selamectin [mi]
avermectin a1a, 25-cyclohexyl-4'-o-de(2,6-dideoxy-3-o-methyl-.alpha.-l-arabino-hexopyranosyl)-5-demethoxy-25-de(1-methylpropyl)-22,23-dihydro-5(hydroxyimino)-, (5z)-
selamectin [usan]
selamectin [ema epar veterinary]
stronghold plus component selamectin
avermectin a1a, 25-cyclohexyl-4'-o-de(2,6-dideoxy-3-o-methyl-.alpha.-l-arabino-hexopyranosyl)-5-demethoxy-25-de(1-methylpropyl)-22,23-dihydro-5-(hydroxyimino)-
selamectin component of stronghold plus
selamectin [usp monograph]
selamectin [inn]
SCHEMBL120105
CS-7778
AKOS026749796
J-014423
mfcd31621085
HY-107212
DB11459
EX-A3581
bdbm50588192
selarid
selamectine
revolt
senergy
selamectin (usp monograph)
selaspot
avermectin a1a, 25-cyclohexyl-4'-o-de(2,6-dideoxy-3-o-methyl-alpha-l-arabino-hexopyranosyl)-5-demethoxy-25-de(1-methylpropyl)-22,23-dihydro-5(hydroxyimino)-, (5z)-
selamectin (ema epar veterinary)
selamectin (usp-rs)
selamectina
selamectinum
selamectin (mart.)
selamectin

Excerpt	Reference	Relevance
" Selamectin was shown to be safe and highly effective in the control of naturally acquired flea infestations on dogs and cats presented as veterinary patients in Europe."	( Efficacy and safety of selamectin against fleas on dogs and cats presented as veterinary patients in Europe. Benchaoui, HA; Clemence, RG; Clements, PJ; Jernigan, AD; Jones, RL; Rowan, TG; Shanks, DJ; Smith, DG; Sture, GH; Watson, P, 2000)	0.31
" There were no serious adverse events."	( Efficacy and safety of selamectin against fleas and heartworms in dogs and cats presented as veterinary patients in North America. Boy, MG; Jernigan, AD; Novotny, MJ; Rowan, TG; Six, RH; Smothers, CD; Thomas, CA, 2000)	0.31
" Thus, selamectin was safe and effective against ear mites in dogs and cats and sarcoptic mange in dogs when used in field (veterinary patient) studies in dogs and cats of a wide variety of ages and breeds."	( Efficacy and safety of selamectin against Sarcoptes scabiei on dogs and Otodectes cynotis on dogs and cats presented as veterinary patients. Behan, S; Benchaoui, HA; Boy, MG; Clemence, RG; Clements, PJ; Jernigan, AD; Rowan, TG; Six, RH; Thomas, CA; Watson, P, 2000)	0.31
" These studies have shown that monthly topical administration of selamectin is safe and highly effective in the treatment of naturally acquired ascarid and hookworm infections in cats."	( Efficacy and safety of selamectin against gastrointestinal nematodes in cats presented as veterinary patients. Benchaoui, HA; Boy, MG; Clemence, RG; Jernigan, AD; Rowan, TG; Six, RH; Smith, DG; Sture, GH; Thomas, CA; Watson, P, 2000)	0.31
" Similarly, selamectin had no adverse effects on reproduction in adult male and female dogs."	( Safety of selamectin in dogs. Ehrhart, JC; Evans, EI; Godin, CS; Jernigan, AD; Krautmann, MJ; McCall, JW; Novotny, MJ; Rowan, TG; Sun, F, 2000)	0.31
" Similarly, selamectin had no adverse effect on reproduction in adult male and female cats."	( Safety of selamectin in cats. De Keulenaer, K; Evans, EI; Godin, CS; Jernigan, AD; Krautmann, MJ; McCall, JW; Novotny, MJ; Rowan, TG; Wang, C, 2000)	0.31
" No adverse reactions associated with selamectin treatment were observed."	( Efficacy and safety of topical administration of selamectin for treatment of ear mite infestation in rabbits. Hair, JA; McTier, TL; Thompson, L; Walstrom, DJ, 2003)	0.32
" No adverse events attributable to treatment with the test articles were observed during the study."	( Safety of imidacloprid plus moxidectin topical solution applied to cats heavily infected with adult heartworms (Dirofilaria immitis). Arther, RG; Atkins, C; Ciszewski, DK; Davis, WL; Ensley, SM; Settje, TL, 2005)	0.33
" Only three mild, possibly drug-related adverse reactions were observed among alI treated animals (two in the imidacloprid/moxidectin group, one in the selamectin group)."	( Efficacy and safety of imidacloprid 10% plus moxidectin 2.5% spot-on in the treatment of sarcoptic mange and otoacariosis in dogs: results af a European field study. Dumont, P; Heine, J; Hellmann, K; Krieger, K, 2005)	0.33
"To determine pharmacokinetics, efficacy, and adverse effects of topically administered selamectin in flea-infested rabbits."	( Pharmacokinetics, efficacy, and adverse effects of selamectin following topical administration in flea-infested rabbits. Carpenter, JW; Dryden, MW; Kukanich, B, 2012)	0.38
" No adverse effects were detected."	( Pharmacokinetics, efficacy, and adverse effects of selamectin following topical administration in flea-infested rabbits. Carpenter, JW; Dryden, MW; Kukanich, B, 2012)	0.38
" No adverse reactions were observed in any of the treated animals."	( Comparison of efficacy, safety, and convenience of selamectin versus ivermectin for treatment of Trixacarus caviae mange in pet guinea pigs (Cavia porcellus). Bdolah-Abram, T; Eshar, D, 2012)	0.38
"The most common adverse event was vomiting (14."	( Safety and efficacy of spinosad chewable tablets for treatment of flea infestations of cats. Kee, EA; Paarlberg, TE; Snyder, DE; Trout, CM; Wiseman, S, 2013)	0.39
" No serious adverse events associated with either product were observed during the study."	( Clinical evaluation of the safety and efficacy of 10% imidacloprid + 2.5% moxidectin topical solution for the treatment of ear mite (Otodectes cynotis) infestations in dogs. Arther, RG; Davis, WL; Jacobsen, JA; Lewis, VA; Settje, TL, 2015)	0.42
" There were no treatment-related adverse events in either study."	( Efficacy and safety of a new topical formulation containing selamectin and sarolaner in the prevention of heartworm disease and the treatment of roundworm infection in cats presented as veterinary patients in Japan. Fujii, T; Maeder, S; Naito, M; Rugg, D; Yonetake, W, 2019)	0.51
"Drug-associated adverse events cause approximately 30 billion dollars a year of added health care expense, along with negative health outcomes including patient death."	( Making Sense of Pharmacovigilance and Drug Adverse Event Reporting: Comparative Similarity Association Analysis Using AI Machine Learning Algorithms in Dogs and Cats. Amini, M; Goligerdian, A; Jaberi-Douraki, M; Mazloom, R; Riviere, J; Staley, J; Wyckoff, GJ; Xu, X, 2019)	0.51
"0 mg/kg sarolaner was safe and highly effective against natural infestations of fleas under a range of geographical conditions, representative of both tropical and subtropical regions of Australia."	( Safety and efficacy of a new spot-on formulation of selamectin plus sarolaner in the treatment and control of naturally occurring flea infestations in cats presented as veterinary patients in Australia. Bruellke, N; Graham, K; Hodge, A; Packianathan, R; Pittorino, M, 2020)	0.56

Excerpt	Reference	Relevance
" There were no selamectin-related adverse effects and no sex differences in pharmacokinetic parameters."	( Pharmacokinetics of selamectin following intravenous, oral and topical administration in cats and dogs. Castledine, J; Jernigan, AD; Rowan, TG; Sarasola, P; Smith, DG; Walker, DK, 2002)	0.31
"Some pharmacokinetic parameters of selamectin were determined in male (n = 5) and female (n = 5) Beagle dogs following a topical application at a dose rate of 6 mg/kg."	( Pharmacokinetics of selamectin in dogs after topical application. Alvinerie, M; Cadiergues, MC; Derlon, AL; Dupuy, J; Franc, M; Sutra, JF, 2004)	0.32
" Pharmacokinetic parameters were determined."	( Pharmacokinetics, efficacy, and adverse effects of selamectin following topical administration in flea-infested rabbits. Carpenter, JW; Dryden, MW; Kukanich, B, 2012)	0.38
"Twenty-one healthy helmeted guineafowl (Numida meleagris) housed at the Oklahoma City Zoo were used to evaluate the pharmacokinetic parameters of topical selamectin."	( Pharmacokinetics of selamectin in helmeted guineafowl (Numida meleagris) after topical administration. Cole, G; D'Agostino, J; Hahn, A; Kukanich, B, 2014)	0.4

Excerpt	Reference	Relevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
" One treatment consisted of the inert formulation ingredients (vehicle) administered as a negative control, and the other three treatments consisted of a single topical dosage of 3, 6, or 9mgkg(-1) of selamectin."	( Dose selection of selamectin for efficacy against adult fleas (Ctenocephalides felis felis) on dogs and cats. Bishop, BF; Evans, NA; Giles, CJ; Gration, KA; Holbert, MS; Jernigan, AD; McTier, TL; Rowan, TG; Smothers, CD, 2000)	0.31
" Animals were randomly allocated to treatment with either selamectin at a minimum dosage of 6mgkg(-1) in the commercial formulation or one of two negative-controls (0."	( Evaluation of the effects of selamectin against adult and immature stages of fleas (Ctenocephalides felis felis) on dogs and cats. Blagburn, BL; Holbert, MS; Jernigan, AD; Jones, RL; McTier, TL; Murphy, MG; Rowan, TG; Shanks, DJ; Smith, DG; Wang, C, 2000)	0.31
" Purpose-bred shorthaired cats and Beagles were randomly allocated to treatment with either selamectin at a minimum dosage of 6mgkg(-1) of body weight in the commercial formulation or the negative control treatment (vehicle only), and housed in controlled simulated home environments capable of supporting the flea life cycle."	( Efficacy of selamectin in the treatment and prevention of flea (Ctenocephalides felis felis) infestations on dogs and cats housed in simulated home environments. Jernigan, AD; Jones, RL; Murphy, MG; Rowan, TG; Shanks, DJ; Smith, DG; Watson, P, 2000)	0.31
" Animals were allocated randomly in a 2:1 ratio to one of two treatments: either selamectin alone at a minimum dosage of 6mgkg(-1) or fenthion at recommended dose rates."	( Efficacy and safety of selamectin against fleas on dogs and cats presented as veterinary patients in Europe. Benchaoui, HA; Clemence, RG; Clements, PJ; Jernigan, AD; Jones, RL; Rowan, TG; Shanks, DJ; Smith, DG; Sture, GH; Watson, P, 2000)	0.31
" In all studies selamectin was applied topically, once per month, in unit doses providing a minimum dosage of 6mgkg(-1)."	( Efficacy and safety of selamectin against fleas and heartworms in dogs and cats presented as veterinary patients in North America. Boy, MG; Jernigan, AD; Novotny, MJ; Rowan, TG; Six, RH; Smothers, CD; Thomas, CA, 2000)	0.31
" Selamectin was applied topically in a single spot to the skin on each animal's back at the base of the neck in front of the scapulae as a unit dose that provided at least the minimum recommended dosage of 6mgkg(-1) (range, 6-12mgkg(-1))."	( Efficacy of selamectin in the prevention of adult heartworm (Dirofilaria immitis) infection in dogs in northern Italy. Clemence, RG; Genchi, C; Jernigan, AD; Rowan, TG; Sarasola, P; Shanks, DJ; Smith, DG, 2000)	0.31
" Cats were treated topically with unit doses providing a minimum dosage of 6mgkg(-1) selamectin at 30 days PI."	( Prevention of experimentally induced heartworm (Dirofilaria immitis) infections in dogs and cats with a single topical application of selamectin. Dickin, SK; Genchi, C; Jernigan, AD; McCall, JW; McTier, TL; Pengo, G; Rowan, TG; Shanks, DJ; Six, RH; Thomas, CA; Watson, P, 2000)	0.31
" In four controlled and masked studies conducted in the USA and Europe, animals were allocated randomly to treatment with either selamectin at a minimum dosage of 6mgkg(-1) (range, 6-12."	( The efficacy of selamectin in the treatment of naturally acquired aural infestations of otodectes cynotis on dogs and cats. Bowman, DD; Genchi, C; Hair, JA; Jernigan, AD; McTier, TL; Pengo, G; Rowan, TG; Shanks, DJ; Smith, DG; Smothers, CD; Thomas, CA; Watson, P, 2000)	0.31
" Unit doses of selamectin (providing a minimum dosage of 6mgkg(-1)) were administered topically to the skin in a single spot at monthly intervals."	( Efficacy and safety of selamectin against gastrointestinal nematodes in cats presented as veterinary patients. Benchaoui, HA; Boy, MG; Clemence, RG; Jernigan, AD; Rowan, TG; Six, RH; Smith, DG; Sture, GH; Thomas, CA; Watson, P, 2000)	0.31
" Unit doses of the commercial formulation of selamectin were administered to the dams to provide at least the minimum recommended dosage of 6mgkg(-1) (range, 6-12mgkg(-1))."	( Efficacy of selamectin administered topically to pregnant and lactating female dogs in the treatment and prevention of adult roundworm (Toxocara canis) infections and flea (Ctenocephalides felis felis) infestations in the dams and their pups. Clements, PJ; Jernigan, AD; Maitland, TP; McLoughlin, A; Murphy, MG; Payne-Johnson, M; Rowan, TG; Shanks, DJ; Sherington, J, 2000)	0.31
" Selamectin was supplied in unit dose tubes designed to deliver a minimum dosage of 6mgkg(-1)."	( Efficacy of selamectin against experimentally induced tick (Rhipicephalus sanguineus and Dermacentor variabilis) infestations on dogs. Chieffo, C; Hair, JA; Jernigan, AD; Krautmann, MJ; McTier, TL; Rowan, TG; Thomas, CA; Wang, C; Young, DR, 2000)	0.31
" Studies were designed to measure the safety of selamectin at the recommended dosage range of 6-12mgkg(-1) of body weight."	( Safety of selamectin in dogs. Ehrhart, JC; Evans, EI; Godin, CS; Jernigan, AD; Krautmann, MJ; McCall, JW; Novotny, MJ; Rowan, TG; Sun, F, 2000)	0.31
" Studies were designed to measure the safety of selamectin at the recommended dosage range of 6-12mgkg(-1) of body weight."	( Safety of selamectin in cats. De Keulenaer, K; Evans, EI; Godin, CS; Jernigan, AD; Krautmann, MJ; McCall, JW; Novotny, MJ; Rowan, TG; Wang, C, 2000)	0.31
" Selamectin was administered topically in a single spot to the skin of each animal's back at the base of the neck in front of the scapulae at a minimum dosage of 6mgkg(-1)."	( Efficacy of selamectin administered topically in the treatment of feline otoacariosis. Blot, C; Bourdoiseau, G; Kodjo, A; Reynaud, MC, 2003)	0.32
" All Sarcoptes-infested dogs were topically treated twice (days 0 and 28) with the dosage recommended by the respective manufacturer (27 dogs with imidacloprid/moxidectin, 26 with selamectin)."	( Efficacy and safety of imidacloprid 10% plus moxidectin 2.5% spot-on in the treatment of sarcoptic mange and otoacariosis in dogs: results af a European field study. Dumont, P; Heine, J; Hellmann, K; Krieger, K, 2005)	0.33
" Results suggested that topical administration at a dosage of 20 mg/kg every 7 days is efficacious for treatment of flea infestation in rabbits."	( Pharmacokinetics, efficacy, and adverse effects of selamectin following topical administration in flea-infested rabbits. Carpenter, JW; Dryden, MW; Kukanich, B, 2012)	0.38
" The new spot-on formulation of selamectin and sarolaner was administered topically once a month for 3 consecutive months at a minimum dosage of 6 mg/kg selamectin (dose range 6-12 mg/kg) plus 1 mg/kg sarolaner (dose range 1-2 mg/kg)."	( Safety and efficacy of a new spot-on formulation of selamectin plus sarolaner in the treatment and control of naturally occurring flea infestations in cats presented as veterinary patients in Australia. Bruellke, N; Graham, K; Hodge, A; Packianathan, R; Pittorino, M, 2020)	0.56

Class	Description
milbemycin
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
67.9K protein	Vaccinia virus	Potency	3.1623	0.0001	8.4406	100.0000	AID720580
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	33.4915	0.0003	23.4451	159.6830	AID743065; AID743067
Cellular tumor antigen p53	Homo sapiens (human)	Potency	33.4915	0.0023	19.5956	74.0614	AID651631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Genome polyprotein	Dengue virus 2 Thailand/16681/84	Ki	63.0000	5.8000	5.8000	5.8000	AID1847507; AID1847535
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (19)

Assay ID	Title	Year	Journal	Article
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347161	Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169	Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347149	Furin counterscreen qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347152	Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347151	Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347155	Optimization screen NINDS Rhodamine qHTS for Zika virus inhibitors: Linked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347150	Optimization screen NINDS AMC qHTS for Zika virus inhibitors: Linked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347168	HepG2 cells viability qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347167	Vero cells viability qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347153	Confirmatory screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID60458	One month protection against adult fleas after single topical application in dog	2001	Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5	Perspectives in animal health: old targets and new opportunities.
AID1847507	Inhibition of DENV2 NS2B-NS3 protease	2021	Bioorganic & medicinal chemistry, 11-01, Volume: 49	A short survey of dengue protease inhibitor development in the past 6 years (2015-2020) with an emphasis on similarities between DENV and SARS-CoV-2 proteases.
AID977599	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1847535	Binding affinity to DENV2 NS2B/NS3 protease assessed as inhibition constant	2021	Bioorganic & medicinal chemistry, 11-01, Volume: 49	A short survey of dengue protease inhibitor development in the past 6 years (2015-2020) with an emphasis on similarities between DENV and SARS-CoV-2 proteases.
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	82 (52.56)	29.6817
2010's	65 (41.67)	24.3611
2020's	9 (5.77)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Trials	61 (39.61%)	5.53%
Reviews	3 (42.86%)	6.00%
Reviews	6 (3.90%)	6.00%
Case Studies	0 (0.00%)	4.05%
Case Studies	10 (6.49%)	4.05%
Observational	0 (0.00%)	0.25%
Observational	0 (0.00%)	0.25%
Other	4 (57.14%)	84.16%
Other	77 (50.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (3)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Detection of Pulmonary Nodules: Comparison of Ultra-low-dose Chest CT (Approaching a Two Views Chest X-ray Radiation) and Standard Low Dose CT. A Monocentric, Prospective, Non-randomized, Comparative, Open-label Study With Blind Reading of the Judgment Cr [NCT03305978]		150 participants (Actual)	Interventional	2017-09-26	Completed
A Study Evaluating the Effect of the Number of Needle Revolutions Inside the Node on the Diagnostic Yield of EBUS-TBNA in Sarcoidosis [NCT02875756]	Phase 2/Phase 3	150 participants (Actual)	Interventional	2016-08-31	Completed
Impact of Fast Gantry Rotation Cardiac CT Angiography on Coronary Motion Artifacts in the Absence of β-Blocker Premedication in Patients Undergoing Aortic Stenosis Workup: a Single-centre Randomized Controlled Trial [NCT05709652]		124 participants (Anticipated)	Interventional	2023-03-01	Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
carprofen carprofen: RN given refers to cpd without isomeric designation. carprofen : Propanoic acid in which one of the methylene hydrogens is substituted by a 6-chloro-9H-carbazol-2-yl group. A non-steroidal anti-inflammatory drug, it is no longer used in human medicine but is still used for treatment of arthritis in elderly dogs.	3.1	1	0	carbazoles; organochlorine compound	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug; photosensitizing agent
omeprazole Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.. omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.. 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.	3.1	1	0	aromatic ether; benzimidazoles; pyridines; sulfoxide
phenylbutazone Phenylbutazone: A butyl-diphenyl-pyrazolidinedione that has anti-inflammatory, antipyretic, and analgesic activities. It has been used in ANKYLOSING SPONDYLITIS; RHEUMATOID ARTHRITIS; and REACTIVE ARTHRITIS.. phenylbutazone : A member of the class of pyrazolidines that is 1,2-diphenylpyrazolidine-3,5-dione carrying a butyl group at the 4-position.	3.1	1	0	pyrazolidines	antirheumatic drug; EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor; metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug
nelfinavir nelfinavir : An aryl sulfide that is used (as its mesylate salt) for treatment of HIV and also exhibits some anticancer properties.. Nelfinavir: A potent HIV protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.	3.41	1	0	aryl sulfide; benzamides; organic heterobicyclic compound; phenols; secondary alcohol; tertiary amino compound	antineoplastic agent; HIV protease inhibitor
epicatechin (-)-epicatechin : A catechin with (2R,3R)-configuration.	3.41	1	0	catechin; polyphenol	antioxidant
benzoic acid [5-amino-1-(4-methoxyphenyl)sulfonyl-3-pyrazolyl] ester [no description available]	3.41	1	0	benzoate ester
1,8-dinitro-4,5-dihydroxyanthraquinone 1,8-dinitro-4,5-dihydroxyanthraquinone: structure in first source	3.41	1	0
tolcapone Tolcapone: A benzophenone and nitrophenol compound that acts as an inhibitor of CATECHOL O-METHYLTRANSFERASE, an enzyme involved in the metabolism of DOPAMINE and LEVODOPA. It is used in the treatment of PARKINSON DISEASE in patients for whom levodopa is ineffective or contraindicated.. tolcapone : Benzophenone substituted on one of the phenyl rings at C-3 and C-4 by hydroxy groups and at C-5 by a nitro group, and on the other phenyl ring by a methyl group at C-4. It is an inhibitor of catechol O-methyltransferase.	3.41	1	0	2-nitrophenols; benzophenones; catechols	antiparkinson drug; EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
peridinin peridinin: structure	3.41	1	0
22,23-dihydroavermectin b(1)a 22,23-dihydroavermectin B1a : A macrocyclic lactone that is avermectin B1a in which the double bond present in the spirocyclic ring system has been reduced to a single bond. It is the major component of ivermectin.. 22,23-dihydroavermectin B(1)a: C48H74O14; major component of IVERMECTIN; MW 875.093; structure given in first source	3.41	1	0	macrocyclic lactone; spiroketal
avermectin b(1)a avermectin B(1)a: RN given refers to avermectin B(1)a; see also avermectins & demethylavermectins	3.1	1	0	avermectin
panduratin a panduratin A: isolated from Kaempferia pandurata; structure in first source	3.41	1	0	diarylheptanoid	metabolite
n,n-(4-xylylidene)bisaminoguanidine N,N'-(p-xylylidene)bis(aminoguanidine) : A guanidine derivative comprised of two carbamimidamido (guanidino) groups, each linked via one of their amino nitrogens to the imino nitrogens of 1,4-phenylenedimethanimine.. N,N-(4-xylylidene)bisaminoguanidine: RN in Chemline for di-HCl: 7044-24-8; RN for unspecified HCl: 62580-72-7	3.41	1	0
tannins gallotannin : A class of hydrolysable tannins obtained by condensation of the carboxy group of gallic acid (and its polymeric derivatives) with the hydroxy groups of a monosaccharide (most commonly glucose).	3.41	1	0	tannin
glycine [no description available]	2.06	1	0	alpha-amino acid; amino acid zwitterion; proteinogenic amino acid; serine family amino acid	EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor; fundamental metabolite; hepatoprotective agent; micronutrient; neurotransmitter; NMDA receptor agonist; nutraceutical
fipronil 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)sulfinyl]-1H-pyrazole-3-carbonitrile : A member of the class of pyrazoles that is 1H-pyrazole that is substituted at positions 1, 3, 4, and 5 by 2,6-dichloro-4-(trifluoromethyl)phenyl, cyano, (trifluoromethyl)sulfinyl, and amino groups, respectively.. fipronil: has low mammalian toxicity; structure given in first source. fipronil : A racemate comprising equimolar amounts of (R)- and (S)-fipronil.	9.1	16	9	(trifluoromethyl)benzenes; dichlorobenzene; nitrile; primary amino compound; pyrazoles; sulfoxide
mebendazole Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.. mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.	9.37	2	2	aromatic ketone; benzimidazoles; carbamate ester	antinematodal drug; microtubule-destabilising agent; tubulin modulator
praziquantel azinox: Russian drug	4.39	2	2	isoquinolines
piperonyl butoxide [no description available]	2.02	1	0	benzodioxoles	pesticide synergist
benzofuran 1-benzofuran : A benzofuran consisting of fused benzene and furan rings. It is the parent compound of the class of 1-benzofurans.. benzofuran: RN & structure given in first source	2.06	1	0	1-benzofurans; benzofuran
isoxazoles isoxazoles : Oxazoles in which the N and O atoms are adjacent.. isoxazole : A monocyclic heteroarene with a structure consisting of a 5-membered ring containing three carbon atoms and an oxygen and nitrogen atom adjacent to each other. It is the parent of the class of isoxazoles.. Isoxazoles: Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions.	5.71	9	2	isoxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
flubendazole flubendazole : A member of the class of mebendazole in which the benzoyl group is replaced by a p-fluorobenzoyl group. A broad-spectrum anthelmintic, it is used, particularly in veterinary medicine, for the treatment of nematodal infections.. flubendazole: the p-fluoro analog of mebendazole	3.39	1	1	aromatic ketone; benzimidazoles; carbamate ester; organofluorine compound	antinematodal drug; teratogenic agent
amitraz amitraz : A tertiary amino compound that is 1,3,5-triazapenta-1,4-diene substituted by a methyl group at position 3 and 2,4-dimethylphenyl groups at positions 1 and 5.. amitraz: ixodicide (tick control); structure	3.53	2	0	formamidines; tertiary amino compound	acaricide; environmental contaminant; insecticide; xenobiotic
permethrin hemoglobin Atlanta-Coventry: Leu replaced by Pro at beta75 and Leu deleted at beta141	4.13	3	1	cyclopropanecarboxylate ester; cyclopropanes	agrochemical; ectoparasiticide; pyrethroid ester acaricide; pyrethroid ester insecticide; scabicide
marbofloxacin [no description available]	2.11	1	0	quinolines
fluphenacur fluphenacur: RN given refers to parent cpd	4.9	2	1	aromatic ether; benzoylurea insecticide; dichlorobenzene; N-acylurea; organofluorine compound
benzofurans Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.	2.06	1	0
stilbenes Stilbenes: Organic compounds that contain 1,2-diphenylethylene as a functional group.. trans-stilbene : The trans-isomer of stilbene.	3.11	1	0	stilbene
sesquiterpenes [no description available]	3.11	1	0
pyrantel Pyrantel: A depolarizing neuromuscular-blocking agent, that causes persistent nicotinic activation resulting in spastic paralysis of susceptible nematodes. It is a drug of second-choice after benzimidazoles for treatment of ascariasis, hookworm, and pinworm infections, being effective after a single dose. (From Smith and Reynard, Textbook of Pharmacology, 1992, p920). pyrantel : A carboxamidine that is 1,4,5,6-tetrahydropyrimidine that is substituted at position 1 by a methyl group and at position 2 by an (E)-2-(2-thienyl)vinyl group. It is used, particularly as the embonate [4,4'-methylenebis(3-hydroxy-2-naphthoate)] salt, as an anthelmintic that is effective against intestinal nematodes including threadworms, roundworms and hookworms, and is included in the WHO 'Model List of Essential Medicines'.	3.39	1	1	1,4,5,6-tetrahydropyrimidines; carboxamidine; thiophenes	antinematodal drug
nitenpyram nitenpyram: a nitromethylene neonicotinoid insecticide; structure in first source. (E)-nitenpyram : A nitenpyram in which the double bond has E configuration.. nitenpyram : A C-nitro compound consisting of 2-nitroethene-1,1-diamine where one of the nitrogens bears ethyl and (6-chloro-3-pyridinyl)methyl while the other nitrogen carries a methyl group.	4.38	2	2	chloropyridyl insecticide; nitenpyram
methoprene Methoprene: Juvenile hormone analog and insect growth regulator used to control insects by disrupting metamorphosis. Has been effective in controlling mosquito larvae.	7.04	1	0	isopropyl 11-methoxy-3,7,11-trimethyldodeca-2,4-dienoate; isopropyl ester	juvenile hormone mimic
cysteine Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.	2.06	1	0	cysteinium	fundamental metabolite
metaflumizone metaflumizone: an insecticide	7.04	1	0	semicarbazone; stilbenoid
doramectin [no description available]	4.09	3	1	macrolide
dextrothyroxine [no description available]	14.1	148	59
acid phosphatase Acid Phosphatase: An enzyme that catalyzes the conversion of an orthophosphoric monoester and water to an alcohol and orthophosphate. EC 3.1.3.2.	2.08	1	0
moxidectin moxidectin: family of macrolide antibiotics with insecticidal & acaricidal activity	7.79	12	5
imidacloprid imidacloprid: systemic & contact insecticide exhibiting low mammalian toxicity; structure given in first source; it is one of the neonicotinoid insecticides, which acts as an antagonist by binding to postsynaptic nicotinic receptors in the insect central nervous system. imidacloprid : An imidazolidine that is N-nitroimidazolidin-2-imine bearing a (6-chloro-3-pyridinyl)methyl substituent at position 1.	9.04	19	12	imidacloprid; imidazolidines; monochloropyridine	environmental contaminant; genotoxin; neonicotinoid insectide; nicotinic acetylcholine receptor agonist; xenobiotic
avermectin avermectin: produced by actinomycete, Streptomyces avermitilis; structure; see also records for specific avermectins. avermectin : Any of the macrolides obtained as fermentation products from the bacterium Streptomyces avermitilis and consisting of a 16-membered macrocyclic backbone that is fused both benzofuran and spiroketal functions and contains a disaccharide substituent. They have significant anthelmintic and insecticidal properties.	11.33	6	2

Condition	Relationship Strength	Studies	Trials
Canine Diseases [description not available]	11.68	47	31
Equine Diseases [description not available]	2.92	1	0
Tick Infestations Infestations with soft-bodied (Argasidae) or hard-bodied (Ixodidae) ticks.	12.35	9	5
Cat Diseases Diseases of the domestic cat (Felis catus or F. domesticus). This term does not include diseases of the so-called big cats such as CHEETAHS; LIONS; tigers, cougars, panthers, leopards, and other Felidae for which the heading CARNIVORA is used.	12.19	65	30
Benign Neoplasms [description not available]	3.03	1	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	3.03	1	0
Congenital Zika Syndrome [description not available]	2.25	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	3.22	5	0
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.25	1	0
Uveal Neoplasms Tumors or cancer of the UVEA.	2.6	1	0
Ancylostomiasis Infection of humans or animals with hookworms of the genus ANCYLOSTOMA. Characteristics include anemia, dyspepsia, eosinophilia, and abdominal swelling.	4.15	3	1
Adverse Drug Event [description not available]	3.38	2	0
Drug-Related Side Effects and Adverse Reactions Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.	3.38	2	0
Flea Infestations Parasitic attack by members of the order SIPHONAPTERA.	6.69	11	5
Dirofilariasis Infection with nematodes of the genus DIROFILARIA, usually in animals, especially dogs, but occasionally in man.	7.33	17	7
Acariasis [description not available]	9.44	34	12
Rodent Diseases Diseases of rodents of the order RODENTIA. This term includes diseases of Sciuridae (squirrels), Geomyidae (gophers), Heteromyidae (pouched mice), Castoridae (beavers), Cricetidae (rats and mice), Muridae (Old World rats and mice), Erethizontidae (porcupines), and Caviidae (guinea pigs).	6.3	13	3
Parasitic Diseases, Animal Animal diseases caused by PARASITES.	2.58	2	0
Ectoparasitic Infestations Infestations by PARASITES which live on, or burrow into, the surface of their host's EPIDERMIS. Most ectoparasites are ARTHROPODS.	10.13	34	25
Toxocariasis Infection by round worms of the genus TOXOCARA, usually found in wild and domesticated cats and dogs and foxes, except for the larvae, which may produce visceral and ocular larva migrans in man.	5.24	4	3
Ear Diseases Pathological processes of the ear, the hearing, and the equilibrium system of the body.	5.61	6	3
Infections, Respiratory [description not available]	2.55	2	0
Respiratory Tract Infections Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases.	2.55	2	0
Disease Exacerbation [description not available]	2.15	1	0
Alcohol Abuse [description not available]	3.09	1	0
Alcoholism A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4)	3.09	1	0
Bancroftian Elephantiasis [description not available]	2.21	1	0
Elephantiasis, Filarial Parasitic infestation of the human lymphatic system by WUCHERERIA BANCROFTI or BRUGIA MALAYI. It is also called lymphatic filariasis.	2.21	1	0
Infections, Nematomorpha [description not available]	2.21	1	0
Infections, Nematode [description not available]	5.87	6	4
Intestinal Diseases, Parasitic Infections of the INTESTINES with PARASITES, commonly involving PARASITIC WORMS. Infections with roundworms (NEMATODE INFECTIONS) and tapeworms (CESTODE INFECTIONS) are also known as HELMINTHIASIS.	3.39	2	0
Helminthiasis Infestation with parasitic worms of the helminth class.	2.21	1	0
Itching [description not available]	2.74	3	0
Mange, Sarcoptic [description not available]	5.85	8	1
Pruritus An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief.	2.74	3	0
Scabies A contagious cutaneous inflammation caused by the bite of the mite SARCOPTES SCABIEI. It is characterized by pruritic papular eruptions and burrows and affects primarily the axillae, elbows, wrists, and genitalia, although it can spread to cover the entire body.	5.85	8	1
Angiostrongylus Infections [description not available]	3.47	1	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.44	2	0
Alcohol Problem [description not available]	2.1	1	0
Alcohol Drinking Behaviors associated with the ingesting of ALCOHOLIC BEVERAGES, including social drinking.	2.1	1	0
Alcohol-Related Disorders Disorders related to or resulting from abuse or misuse of alcohol.	2.1	1	0
Disease, Pulmonary [description not available]	2.1	1	0
Lung Diseases Pathological processes involving any part of the LUNG.	2.1	1	0
Zoonoses Diseases of non-human animals that may be transmitted to HUMANS or may be transmitted from humans to non-human animals.	2.74	3	0
Angiomatosis, Bacillary A reactive vascular proliferation that is characterized by the multiple tumor-like lesions in skin, bone, brain, and other organs. Bacillary angiomatosis is caused by infection with gram-negative Bartonella bacilli (such as BARTONELLA HENSELAE), and is often seen in AIDS patients and other IMMUNOCOMPROMISED HOSTS.	2.11	1	0
ER-Negative PR-Negative HER2-Negative Breast Cancer [description not available]	2.11	1	0
Triple Negative Breast Neoplasms Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.	2.11	1	0
Buruli Ulcer Disease [description not available]	2.11	1	0
Buruli Ulcer A lesion in the skin and subcutaneous tissues due to infections by MYCOBACTERIUM ULCERANS. It was first reported in Uganda, Africa.	7.11	1	0
Avian Diseases [description not available]	2.47	2	0
Capillaria hepatica Infection [description not available]	2.04	1	0
Helminthiasis, Animal Infestation of animals with parasitic worms of the helminth class. The infestation may be experimental or veterinary.	2.96	1	0
Fungal Diseases [description not available]	3.85	2	1
Mycoses Diseases caused by FUNGI.	3.85	2	1
Aspiculariasis [description not available]	4.11	3	1
Emesis [description not available]	2.05	1	0
Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.	2.05	1	0
Vomiting The forcible expulsion of the contents of the STOMACH through the MOUTH.	2.05	1	0
Tuberculosis, Drug-Resistant [description not available]	2.08	1	0
Koch's Disease [description not available]	2.08	1	0
Tuberculosis Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.	2.08	1	0
Tuberculosis, Multidrug-Resistant Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.	2.08	1	0
Trombiculiasis Infestation with mites of the genus Trombicula, whose larvae carry the rickettsial agent of scrub typhus.	2.07	1	0
Bacterial Disease [description not available]	3.46	1	1
External Ear Inflammation [description not available]	3.46	1	1
Bacterial Infections Infections by bacteria, general or unspecified.	3.46	1	1
Otitis Externa Inflammation of the OUTER EAR including the external EAR CANAL, cartilages of the auricle (EAR CARTILAGE), and the TYMPANIC MEMBRANE.	8.46	1	1
Pediculosis [description not available]	3.4	1	1
Lice Infestations Parasitic attack or subsistence on the skin by members of the order Phthiraptera, especially on humans by Pediculus humanus of the family Pediculidae. The hair of the head, eyelashes, and pubis is a frequent site of infestation. (From Dorland, 28th ed; Stedman, 26th ed)	3.4	1	1
Allergic Contact Dermatitis [description not available]	3.4	1	1
Dermatitis, Allergic Contact A contact dermatitis due to allergic sensitization to various substances. These substances subsequently produce inflammatory reactions in the skin of those who have acquired hypersensitivity to them as a result of prior exposure.	3.4	1	1
Cholera Infantum [description not available]	3.82	2	1
Alopecia Cicatrisata [description not available]	2.03	1	0
Alopecia Absence of hair from areas where it is normally present.	2.03	1	0
Monkey Diseases Diseases of Old World and New World monkeys. This term includes diseases of baboons but not of chimpanzees or gorillas (= APE DISEASES).	3.43	1	1
Toxascariasis Infections with nematodes of the genus TOXASCARIS.	3.39	1	1
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	5	3	3
Creeping Eruption [description not available]	2.01	1	0

selamectin

Description

Cross-References

Synonyms (59)

Research Excerpts

Toxicity

Pharmacokinetics

Bioavailability

Dosage Studied

Drug Classes (1)

Protein Targets (4)

Potency Measurements

Inhibition Measurements

Biological Processes (124)

Molecular Functions (34)

Ceullar Components (19)

Bioassays (19)

Research

Studies (156)

Study Types

Clinical Trials (3)

Trial Overview

selamectin

Description

Cross-References

Synonyms (59)

Research Excerpts

Toxicity

Pharmacokinetics

Bioavailability

Dosage Studied

Drug Classes (1)

Protein Targets (4)

Potency Measurements

Inhibition Measurements

Biological Processes (124)

Molecular Functions (34)

Ceullar Components (19)

Bioassays (19)

Research

Studies (156)

Study Types

Clinical Trials (3)

Trial Overview

Related Drugs (40)

Related Conditions (78)